Inventor · disambiguated record
Thomas Daniel Heightman
Also filed as: HEIGHTMAN THOMAS D · HEIGHTMAN THOMAS DANIEL · HEIGHTMAN THOMAS DAVID
22 granted patents·26 pending applications·78 citations·filing 2001–2024
94Inventor score
Files withGLAXOSMITHKLINE IP DEV LTD12ASTEX THERAPEUTICS LTD9GLAXO GROUP LTD6OTSUKA PHARMA CO LTD6HEER JAG PAUL5
Top patents by PatentIndex Score
48 records- 0192US11866428B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 9, 2024·2 cites·21 claims
- 0292US11001575B1Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2019·Granted May 11, 2021·4 cites·26 claims
- 0391US10457669B2Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2016·Granted Oct 29, 2019·5 cites·25 claims
- 0491US9980973B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Granted May 29, 2018·6 cites·21 claims
- 0590US10485806B2Nrf2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Granted Nov 26, 2019·3 cites·10 claims
- 0690US9676768B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2015·Granted Jun 13, 2017·8 cites·16 claims
- 0788US10272095B2NRF2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Apr 30, 2019·4 cites·18 claims
- 0887US9018214B2Bicyclic heterocycle compounds and their uses in therapyWOOLFORD ALISON JO-ANNE·Filed 2012·Granted Apr 28, 2015·13 cites·21 claims
- 0985US2024199607A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1084US9663512B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2013·Granted May 30, 2017·8 cites·18 claims
- 1183US7615550B2Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonistsGLAXO GROUP LTD·Filed 2003·Granted Nov 10, 2009·17 cites·19 claims
- 1282US10604509B2Nrf2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Mar 31, 2020·2 cites·26 claims
- 1382US2024368136A1Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1481US2025084077A1Ether linked triazoles as nrf2 activatorsASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 1577US10364256B2Biaryl pyrazoles as NRF2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jul 30, 2019·2 cites·15 claims
- 1675US10144731B2Nrf2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Dec 4, 2018·2 cites·12 claims
- 1772US11939321B2Benzolactam compounds as protein kinase inhibitorsOTSUKA PHARMA CO LTD·Filed 2021·Granted Mar 26, 2024·0 cites·28 claims
- 1872US8222245B2Oxadiazole derivatives active on sphingosine-1-phosphate (S1P)DEMONT EMMANUEL HUBERT·Filed 2008·Granted Jul 17, 2012·1 cites·5 claims
- 1971US8278324B2Oxadiazole derivatives active on sphingosine-1-phosphate (S1P)HEER JAG PAUL·Filed 2008·Granted Oct 2, 2012·1 cites·3 claims
- 2069US12091409B2Ether linked triazoles as NRF2 activatorsASTEX THERAPEUTICS LTD·Filed 2021·Granted Sep 17, 2024·0 cites·9 claims
- 2169US2023047296A1Nrf2 REGULATORSGLAXOSMITHKLINE IP DEV LTD·Filed 2021·Application pending·0 cites
- 2267US2019375748A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2365US2024131169A1Cliptac compositionOTSUKA PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 2464US11059816B2Ether linked triazoles as NRF2 activatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Granted Jul 13, 2021·0 cites·4 claims
- 2561US2017334907A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Application pending·0 cites
- 2659US2010075953A1Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonistsGLAXO GROUP LTD·Filed 2009·Application pending·0 cites
- 2758US2020079759A1Nrf2 REGULATORSGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
- 2858US2010174065A1CompoundsGLAXO GROUP LTD·Filed 2009·Application pending·0 cites
- 2953US11786600B2Cliptac compositionOTSUKA PHARMA CO LTD·Filed 2017·Granted Oct 17, 2023·0 cites·25 claims
- 3051US8263620B2Oxadiazole derivatives active on sphingosine-1-phosphate (SIP)HEER JAG PAUL·Filed 2008·Granted Sep 11, 2012·0 cites·4 claims
- 3150US2019002454A1NRF2 RegulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3249US2010267734A1N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulatorGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 3348US2010261767A1Oxadiazole derivatives for use as s1p1 agonists in the treatment of autoimmune and inflammatory disordersHEER JAG PAUL·Filed 2008·Application pending·0 cites
- 3448US2010273770A11, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseasesHEER JAG PAUL·Filed 2008·Application pending·0 cites
- 3545US8329730B2CompoundsHEIGHTMAN THOMAS DANIEL·Filed 2009·Granted Dec 11, 2012·0 cites·4 claims
- 3644US2007185089A1Benzazepine derivatives for the treatment of neurological and psychiatric disordersGLAXO GROUP LTD·Filed 2005·Application pending·0 cites
- 3743US2006019964A1CompoundsANCLIFF RANCHAEL A·Filed 2005·Application pending·0 cites
- 3843US2006052597A1Aryloxyalkylamine derivatives as h3 receptor ligandsBEST DESMOND J·Filed 2003·Application pending·0 cites
- 3942US2008009479A1Tetrahydrobenzazepines as Histamine H3 Receptor LigandsGLAXO GROUP LTD·Filed 2005·Application pending·0 cites
- 4041US2020071310A1N-aryl pyrazoles as nrf2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 4141US2004266842A1Thiazolyl substituted triazoles as alk5 inhibitorsGASTER LARAMIE MARY·Filed 2002·Application pending·0 cites
- 4241US2005014938A1Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinaseFiled 2002·Application pending·0 cites
- 4341US2010152235A1Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)HEER JAG PAUL·Filed 2010·Application pending·0 cites
- 4441US2005239797A1Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activitySMITHKLINE BEECHAM PLC·Filed 2005·Application pending·0 cites
- 4539US2020031820A13-carboxylic acid pyrroles as nrf2 regulatorsGLSXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD·Filed 2017·Application pending·0 cites
- 4639US2004152738A1Pyridyl-substituted triazoles as tgf inhibitorsFiled 2001·Application pending·0 cites
- 4737US10351530B2Arylcyclohexyl pyrazoles as NRF2 regulatorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Jul 16, 2019·0 cites·8 claims
- 4837US2018179167A1Nrf2 REGULATORSGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas Daniel Heightman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →